Global Home - News and Events - Press Releases and News Archive - Xellia Pharmaceuticals demonstrates commitment to the fight against sepsis by providing support for Sepsis Awareness Month

Xellia Pharmaceuticals demonstrates commitment to the fight against sepsis by providing support for Sepsis Awareness Month

Copenhagen, Denmark, 29 September 2020 - Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, announces support for Sepsis Awareness Month.

Sepsis is the third leading cause of death after heart disease and cancer in the USi , affecting more than 1.7 million peopleii  and killing more than 270,000 people within a single yeariii

September has been designated as Sepsis Awareness Month by the Sepsis Alliance since 2011, with individuals, healthcare professionals, businesses and organizations from all areas of medicine, invited to help raise awareness each year.

In 2019, Xellia Chicago participated in a Sepsis 5k run to increase awareness around the disease. As a result of the COVID-19 crisis in 2020, the annual event cannot be held in person this year, therefore, Xellia Chicago instead led a company-wide Sepsis Virtual Run Challenge. On a global scale, on 26 September 2020, Xellia employees across 5 countries walked and ran 5 km distances to increase awareness.

Craig Boyd, President, Xellia North America, commented: “One in five deaths worldwide are due to sepsis, and it is the leading cause of death in US hospitalsiv. At Xellia, we are proud to manufacture and produce key anti-infectives, to combat sepsis, and we understand the importance of delivering a consistent and reliable supply. 

“On behalf of the Xellia team, I’d like to thank every employee around the globe for joining Xellia Chicago in our Sepsis Virtual Run Challenge, and the provided support.”

 

Download as PDF

 

For more information, please contact:

 

Xellia Pharmaceuticals
Carl-Åke Carlsson, CEO
Tel:+45 32 64 55 00

Instinctif Partners (International media relations)
Melanie Toyne-Sewell / Siobhan Sanford
Tel: +44 (0) 7890 022 814 / +44 (0) 7534 247 411
Email: xellia@instinctif.com


i JAMA. 2014;312(1):90-92. 2. Rhee C, Dantes R, Epstein L, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. JAMA. 2017;318(13):1241-1249.
ii Rhee C, Dantes R, Epstein L, et al. Incidence and trends of sepsis in US hospitals using clinical vs claims data, 2009-2014. JAMA. 2017;318(13):1241-1249
iii Centers for Disease Control and Prevention. Leading causes of death. https://www.cdc.gov/nchs/fastats/leading-causes-of-death.html. Accessed August 27, 2020
iv Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200–211.